EUCTR2018-002675-17-DE进行中（未招募）1 期
Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD - Q-HAM
Ruprecht-Karls-University of Heidelberg Medical Faculty represented in law by Heidelberg University Hospital0 个研究点目标入组 80 人开始时间: 2019年8月13日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Patients with acute myeloid leukemia according to the 2016 WHO classification (except acute promyelocytic leukemia) who are either
- •A)refractory to induction therapy or
- •B)relapsed after first line treatment including chemotherapy, autologous and/or allo-HCT (details below).
- •2.Positive for FLT3-ITD (defined as a ratio of mutant to wild-type alleles of at least 0.05; measured within 4 weeks before inclusion)#
- •3.ECOG performance status = 2. See appendix 18.1
- •4.Adequate renal function defined as creatinine clearance >50 mL/min (calculated using the standard method for the institution)
- •5.Discontinuation of prior AML treatment for at least
- •10 days for cytotoxic agents and
- •28 days for investigational drug treatment
- •before the start of study treatment (except hydroxyurea to control hyperleukocytosis)
- •6.Age = 18 years and = 75 years
- •7.Pregnancy and childbearing potential:
- •Non-pregnant and non-nursing women
- •Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL within 48 hours prior to randomization (Women of childbearing potential” is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months).
- •WOCBP must agree to avoid getting pregnant while on therapy: WOCBP must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal ligation, or partner’s vasectomy) during study and 6 months after end of study/treatment.
- •Men must use a latex condom during any sexual contact with WOCBP, even if they have undergone a successful vasectomy and must agree to avoid to father a child during study and 6 months after end of study/treatment
- •8.Signed written informed consent
- •9.Ability of patient to understand character and consequences of the clinical trial
- •A)Refractory to induction therapy is defined as no CR, or CRi, or PR (according to standard criteria) [1] after 1 or 2 intensive induction cycles of at least 7 days of cytarabine 100-200mg/m² continuously or an equivalent regimen with cytarabine with total dose not less than 700mg/m² per cycle and 2 days of an anthracycline (e.g. daunorubicin, idarubicin).
- •B)Relapsed after first line therapy is defined as relapsed AML (according to standard criteria) [1] after a first line therapy including at least one intensive induction and consolidation therapy including (but not limited to) allo-HCT.
- •# Secondary exclusion if FLT3-ITD cannot be verified by central testing. Patient already receiving Quizartinib may continue taking it and will be excluded after the first treatment cycle.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 70
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1.Acute promyelocytic leukemia (AML FAB M3 with t(15;17)(q22;q12) / PML-RARA)
- •2.Patients with known CNS leukemia
- •3.Isolated extramedullary manifestation of AML
- •4.Patients with a currently active” second malignancy other than non-melanoma skin cancer. Patients are not considered to have a currently active” malignancy if they have completed therapy for more than one year and are considered by their physician to be at less than 30% risk of relapse within one year
- •5.Hyperleukocytosis (leukocytes > 30,000/µl) at the time of study entry. 1)
- •6.Uncontrolled or significant cardiovascular disease, including any of the following:
- •oHistory of heart failure NYHA class 3 or 4
- •oLeft ventricular ejection fraction (LVEF) = 40% by echocardiogram (ECHO)
- •oHistory of uncontrolled angina pectoris or myocardial infarction within 12 months prior to screening
- •oHistory of second (Mobitz II) or third degree heart block or any cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)
- •7.Inadequate liver function: ALT and AST = 2.5 x ULN), total bilirubin = 1.5 x ULN; Alkaline phosphatase = 2.5 x ULN. Known liver cirrhosis or history of veno-occlusive disease (VOD) or history of Sinusoidal Obstruction Syndrome (SOS)
- •8.Known positivity for HIV, active HBV, HCV or hepatitis A infection (active hepatitis B defined by HBs Ag positivity, active hepatitis C defined by positive virus load)
- •9.Uncontrolled active infection
- •10.Evidence or history of severe non-leukemia associated bleeding diathesis or coagulopathy
- •11.within 100 days after allo-HCT
- •12.clinically relevant Graft-versus-Host-Disease (GvHD) requiring initiation of treatment or treatment escalation within 21 days prior to screening
- •13.Any one of the following ongoing or in the previous 6 months: congenital long QT syndrome, Torsades de pointes, arrhythmias (including sustained ventricular tachyarrhythmia), right or left bundle branch block and bifascicular block, unstable angina, coronary/peripheral artery bypass graft, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism; as well as bradycardia defined as <50 bpms
- •14.QTc interval >450 msec using the Fredericia correction (QTcF).
- •15.Patients known to be refractory to platelet or packed red cell transfusions as per institutional guidelines, or who are known to refuse or who are likely to refuse blood product support.
- •16.Severe neurologic or psychiatric disorder interfering with ability of giving informed consent
- •17.Known or suspected active alcohol or drug abuse
- •18.No consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician about study participation.
- •19.Pregnancy and lactation
- •20.History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
- •21.Prior treatment with quizartinib
- •1)These patients should be treated with hydroxyurea according to routine practice and are only allowed to enter into the study when leukocyte counts of 30,000/µl or below are reached. If hydroxyurea is not sufficient to control hyperleukocytosis, i.v. application of 100mg cytarabine continuously over 24 hours may be discussed with the Principle Investigator or the Medical Coordinator.
研究者
相似试验
终止
2 期
Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITDAML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)NCT03989713Prof. Dr. Richard F Schlenk11
进行中（未招募）
3 期
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLLeukemiaNCT06578247Daiichi Sankyo700
招募中
1 期
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid LeukemiaNCT03661307M.D. Anderson Cancer Center73
已完成
2 期
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AMLAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT00774046University of Chicago32
进行中（未招募）
2 期
Biomarker study of Quizartinib resistance mechanisms and outcomes in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemiaAcute myeloid leukemiaJPRN-jRCTs071200015Harada Mine51